Table 3. Prognostic value of clinicopatholgic factors and candidate biomarkers.
Characters | Univariate analyisis | Multivariate analyisis | |||
---|---|---|---|---|---|
5-year survival rate | P* | HR | 95%CI | P# | |
Gender | |||||
Male | 37.4 | 0.065 | |||
Female | 58.6 | ||||
Age | |||||
< 60 | 49.6 | 0.666 | |||
≥ 60 | 45.3 | ||||
Tumor diameter (cm) | |||||
≤ 5 | 41.8 | 0.862 | |||
> 5 | 49.6 | ||||
Differentiation | |||||
Well + Moderate | 57.7 | 0.124 | |||
Poor | 34.1 | ||||
Tumor invasion | |||||
T1 + T2 | 58.6 | 0.015 | 1 | ||
T3 + T4 | 37.9 | 1.97 | 0.92–4.19 | 0.079 | |
Lymph node invasion | |||||
No (N0) | 80 | P < 0.001 | 1 | ||
Yes (N1/2/3) | 6.9 | 15.6 | 5.42–45.3 | P < 0.001 | |
Distant metastasis | |||||
M0 | 49.6 | P < 0.001 | 1 | ||
M1 | 0 | 4.15 | 1.55–11.1 | 0.005 | |
TNM stage | |||||
I | 75 | P < 0.001 | |||
II | 57.6 | ||||
III | 38.6 | ||||
IV | 0 | ||||
Lauren subtype | |||||
Intestinal | 59 | 0.009 | |||
Diffuse | 24 | ||||
Mixed | 32.6 | ||||
Peritoneal dissemination | |||||
Yes | 0 | 0.007 | |||
No | 47.6 | ||||
FGFR2 | |||||
low | 52.2 | 0.031 | 1 | ||
high | 35.9 | 1.22 | 0.65–2.26 | 0.537 | |
SPRY1 | |||||
low | 46.8 | 0.577 | |||
high | 46.8 | ||||
SPRY2 | |||||
low | 43.2 | 0.020 | 1 | ||
high | 61.3 | 0.61 | 0.28–1.33 | 0.216 | |
SPRY3 | |||||
low | 47.1 | 0.737 | |||
high | 0 | ||||
SPRY4 | |||||
low | 48.2 | 0.947 | |||
high | 39.5 |
means calculated by log-rank test, #means calculated by Cox-regression hazard model,
Abbreviations: FGFR2 = fibroblast growth factor receptor 2, SPRY = sprouty, HR = hazard ratio, CI = confidence internal.